Sun Pharmaceutical Industries informs about press release

16 Oct 2023 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed its Press Release relating to ‘Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma’. 

The above information is a part of company’s filings submitted to BSE.


Sun Pharma Inds. Share Price

1777.45 33.10 (1.90%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×